Web of knowledge for
IMA - HEALTH
Contract number 481 PED /2020
National Authority: UEFISCDI
UNIVERSITATEA BABES BOLYAI
FACULTATEA DE CHIMIE SI INGINERIE CHIMICA
Innovative materials as dietary supplements for healthcare, IMA-HEALTH
· Obtained results:
Study design of IMA-HEALTH and preliminary results
Review of existing technical documentation, industrial research, pursues the review of existing documentation and bioavailability of food supplements to choose the optimal solutions for preparation methods of IMA-HEALTH materials (TRL4).
Considerations for bioavailability of dietary supplements. It will accomplish a documentary study regarding intake and bioavailability of nutrients of interest, matrix and host factors, influence on the bioavailability of dietary supplements, risk-benefit-implications assessment of dietary supplements based on hydroxyapatite.
Detailed design of in vitro experiments for testing
innovative materials - first part. Adaptation of testing methods to
physical and pharmaceutical formulation of material, establishing the acute/subacute/chronic
classs of testing design, setting seriate concentration domain considering
the already existing literature data as well as corsortia experience
regarding the inner theoretical biocompatibility of innovative material are
going to be considered.
Realization of IMA-HEALTH materials at TRL3 level
*Development of synthetic sub-micron hydroxyapatite and complex with D3 and K2 vitamin materials. It will be developed 2 preparation methods for pure HAP and HAP/vitamin.
*Experimentation and physico-chemical characterization of IMA-HEALTH materials. Release profile of active ingredients. A series of experiments will be performed for the physical-chemical characterization of the IMA-HEALTH products, using advanced methods for structural characterization.
*Detailed design of in vitro experiments for testing innovative materials - final part. Dynamic in vitro platforms, as well as different tridimensional and co-culturing systems options are going to be analyzed and the optimal system is going to be selected according to the material property.
*Analysis and interpretation of obtained results for optimization. The results obtained will be analyzed. The results will form the basis for optimized IMA-HEALTH materials at TRL3 level.
*In vitro testing of newly designed construct on osteoblast cell line. Therapeutic effect on osteoporosis will be tested using MC3T3-E1 osteoblastic cell line.
*Optimization of IMA-HEALTH EM. Characterization of optimized IMA-HEALTH EM. Verification of IMA-HEALTH materials. Based on the obtained results, the materials with appropriate characteristics to the goal of project will be chosen for optimization, incorporation in dietary supplements and potential marketing.
*In vitro testing of synthesis drug on human endothelium. HUVEC cell line is going to be used as cellular model for understanding effects following endothelium exposure to HAP or ms-HAP, and their complexes with vitamin D3 and vitamin K2.